Method and compositions

Patent metadata

Field	Value
Publication number	US-10485865-B2
Application number	US-201615242904-A
Country	US
Kind code	B2
Filing date	Aug 22, 2016
Priority date	Mar 2, 2007
Publication date	Nov 26, 2019
Grant date	Nov 26, 2019

Abstract

The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants.

First claim

The invention claimed is:

1. A vaccine composition comprising (i) one or more first immunogenic polypeptides derived from Mycobacterium tuberculosis ; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said Mycobacterium tuberculosis ; and (iii) an adjuvant;
wherein all of said immunogenic polypeptides have a sequence identity greater than 80% to SEQ ID NO: 10.

2. The vaccine composition according to claim 1 wherein one or more of said immunogenic polypeptides have a sequence identity greater than 90% to SEQ ID NO: 10.

3. The vaccine composition according to claim 2 wherein one or more of said immunogenic polypeptides comprises residues 4-725 of SEQ ID NO: 10.

4. The vaccine composition according to claim 1 wherein one or more of any of the said immunogenic polypeptides comprise TbH9 (Mtb39a), wherein TbH9 (Mtb39a) is residues 139-528 of SEQ ID NO: 10.

5. The vaccine composition according to claim 1 wherein one or more of the adenoviral vectors is a human adenovirus.

6. The vaccine composition according to claim 1 wherein one or more of the adenoviral vectors is replication defective.

7. A kit comprising (i) one or more first immunogenic polypeptides derived from Mycobacterium tuberculosis ; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said Mycobacterium tuberculosis ; and (iii) an adjuvant;
wherein all of said immunogenic polypeptides have a sequence identity greater than 80% to SEQ ID NO: 10.

Assignees

• Glaxosmithkline Biologicals Sa

Inventors

• Voss Gerald Hermann

Classifications

• A61K39/015

  Hemosporidia antigens, e.g. Plasmodium antigens · CPC title

• A61K39/21 Primary

  Retroviridae, e.g. equine infectious anemia virus · CPC title

• A61K2039/55577

  Saponins; Quil A; QS21; ISCOMS · CPC title

• A61K2039/5254

  avirulent or attenuated · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title